CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma
Crwe World,
New indication for this one-time infusion may provide patients with a treatment-free respite as early as first relapse SOMERSET…